Skip to content
HowShorted

RIGEL PHARMACEUTICALS INC short interest in 2018

In 2018, RIGEL PHARMACEUTICALS INC's disclosed short interest ran from 5.86% of shares outstanding on 12 Jan 2018 to 10.79% on 31 Dec 2018, a change of +4.93 percentage points. The year's high was 11.62% on 31 Oct 2018 and its low 4.86% on 31 May 2018, averaging 8.26% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 13.51 days on 13 Jul 2018. Full history: RIGEL PHARMACEUTICALS INC.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for RIGEL PHARMACEUTICALS INC in 2018

2018 in figures

Start of year
5.86% (12 Jan 2018)
End of year
10.79% (31 Dec 2018)
Change
+4.93 pp
High
11.62% (31 Oct 2018)
Low
4.86% (31 May 2018)
Average
8.26%
Highest days to cover
13.51 (13 Jul 2018)
SEC filings marked
10

Every report in 2018

RIGEL PHARMACEUTICALS INC short interest in 2018
SettlementShort interestDays to coverFilings since previous
12 Jan 20185.86%7.01results (8-K)
31 Jan 20185.82%5.80
15 Feb 20186.35%8.15
28 Feb 20186.34%11.14
15 Mar 20186.20%6.3810-K filed, results (8-K)
29 Mar 20186.56%5.63
13 Apr 20187.29%2.05
30 Apr 20185.33%1.34results (8-K)
15 May 20184.91%3.5710-Q filed, results (8-K)
31 May 20184.86%4.65
15 Jun 20186.60%2.66
29 Jun 20188.84%5.38
13 Jul 20189.04%13.51
31 Jul 201810.14%7.92
15 Aug 201810.74%10.2210-Q filed, results (8-K)
31 Aug 20189.64%5.34
14 Sep 20189.92%7.20
28 Sep 201810.01%4.58
15 Oct 201810.91%6.36
31 Oct 201811.62%11.07
15 Nov 201811.48%10.0310-Q filed, results (8-K)
30 Nov 20189.93%11.23
14 Dec 20188.96%5.52
31 Dec 201810.79%5.93

See also: RIGEL PHARMACEUTICALS INC's full history · most shorted US stocks of 2018 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.